Oric Pharmaceuticals (NASDAQ:ORIC) CEO Jacob Chacko Sells 33,374 Shares

by · The Markets Daily

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) CEO Jacob Chacko sold 33,374 shares of the stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $9.06, for a total value of $302,368.44. Following the transaction, the chief executive officer owned 581,711 shares of the company’s stock, valued at approximately $5,270,301.66. This trade represents a 5.43% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Jacob Chacko also recently made the following trade(s):

  • On Monday, October 6th, Jacob Chacko sold 37,461 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $12.32, for a total value of $461,519.52.
  • On Wednesday, October 1st, Jacob Chacko sold 53,001 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $12.05, for a total value of $638,662.05.
  • On Tuesday, September 30th, Jacob Chacko sold 34,538 shares of Oric Pharmaceuticals stock. The stock was sold at an average price of $12.01, for a total value of $414,801.38.
  • On Monday, September 22nd, Jacob Chacko sold 125,000 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $10.80, for a total value of $1,350,000.00.

Oric Pharmaceuticals Stock Performance

NASDAQ ORIC traded down $0.00 during trading on Thursday, hitting $8.22. The stock had a trading volume of 104,092 shares, compared to its average volume of 1,169,781. Oric Pharmaceuticals, Inc. has a 12 month low of $3.90 and a 12 month high of $14.93. The company’s 50-day moving average price is $11.94 and its two-hundred day moving average price is $10.98. The company has a market capitalization of $800.16 million, a PE ratio of -4.75 and a beta of 1.32.

Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.08. As a group, equities analysts anticipate that Oric Pharmaceuticals, Inc. will post -2.17 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on ORIC shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research report on Wednesday, October 8th. Guggenheim assumed coverage on Oric Pharmaceuticals in a research note on Thursday, September 4th. They issued a “buy” rating and a $18.00 price target for the company. HC Wainwright boosted their price target on Oric Pharmaceuticals from $19.00 to $23.00 and gave the stock a “buy” rating in a research report on Friday, November 14th. JPMorgan Chase & Co. upped their price objective on Oric Pharmaceuticals from $17.00 to $20.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 18th. Finally, Wolfe Research assumed coverage on shares of Oric Pharmaceuticals in a research note on Tuesday, November 18th. They issued a “peer perform” rating for the company. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $19.67.

Check Out Our Latest Analysis on ORIC

Hedge Funds Weigh In On Oric Pharmaceuticals

Large investors have recently modified their holdings of the stock. Vivo Capital LLC increased its position in Oric Pharmaceuticals by 50.3% during the second quarter. Vivo Capital LLC now owns 3,126,604 shares of the company’s stock worth $31,735,000 after acquiring an additional 1,046,154 shares during the period. JPMorgan Chase & Co. grew its position in shares of Oric Pharmaceuticals by 3,646.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,335,448 shares of the company’s stock worth $13,555,000 after purchasing an additional 1,299,799 shares in the last quarter. Rafferty Asset Management LLC grew its position in shares of Oric Pharmaceuticals by 50.7% during the 1st quarter. Rafferty Asset Management LLC now owns 77,424 shares of the company’s stock worth $432,000 after purchasing an additional 26,032 shares in the last quarter. Alkeon Capital Management LLC increased its holdings in shares of Oric Pharmaceuticals by 12.5% during the second quarter. Alkeon Capital Management LLC now owns 4,504,096 shares of the company’s stock worth $45,717,000 after purchasing an additional 500,000 shares during the period. Finally, Nuveen LLC acquired a new stake in shares of Oric Pharmaceuticals in the first quarter valued at approximately $935,000. 95.05% of the stock is owned by institutional investors.

Oric Pharmaceuticals Company Profile

(Get Free Report)

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.

Further Reading